3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Spinal Cord Neoplasms
1
Pituitary Neoplasms
1
Parkinson Disease
1
Nervous System Diseases
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Hematologic Diseases
1
Epilepsy
1
Brain Neoplasms
1
Bone Marrow Diseases
1
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ruxolitinib
1
ponatinib
1
fludarabine phosphate
1
fludarabine
1
Whole-Body Irradiation
1
Tacrolimus
1
Quality of Life
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Electrocardiography
1
Cyclophosphamide
1
Clinical Laboratory Techniques
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Bone Marrow Examination
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Marrow Diseases
×
Clinical Laboratory Techniques
×
90 days
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled